jRCT2080220095未知N/a
A confirmatory study of APTA-2217 in patients with chronic obstructive pulmonary disease (A placebo-controlled double-blind, parallel group study)
Mitsubishi Tanabe Pharma was the original trial sponsor; however Astra Zeneca is now the Responsible Party0 个研究点开始时间: 待定
试验速览
- 阶段
- N/a
- 发起方
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Double-blind, parallel-group comparative clinical study
入排标准
- 年龄范围
- 40age old over 至 No limit（—）
- 性别
- All
入选标准
- •[Inclusion criteria]
- •Patients with chronic obstructive pulmonary disease who are 40 years old or more, current smoker or ex-smoker, 30 to 80 % of predicted FEV1 after inhalation of short acting beta stimulant.
- •[Exclusion criteria]
- •Patients with poorly controlled COPD, patients who need for long-term oxygen therapy, patients who have concurrent respiratory diseases such as asthma, diffuse panbronchiolitis, congenital sinobronchial syndrome, bronchiolitis obliterans, bronchiectasis, active tuberculosis, pneumoconiosis, pulmonary lymph vascular myaoma), which are considered to affect the evaluation.
排除标准
- 未提供
结局指标
主要结局
-
Efficacy (pulmonary function test), safety and pharmacokinetics
次要结局
未报告次要终点
研究者
相似试验
未知
Unknown
A confirmatory study of APTA-2217 in patients with chronic obstructive pulmonary disease (A placebo-controlled double-blind, parallel group study)JPRN-jRCT2080220095Mitsubishi Tanabe Pharma was the original trial sponsor; however Astra Zeneca is now the Responsible Party
未知
Unknown
A confirmatory study of APTA-2217 in adult patients with bronchial asthma (A placebo-controlled double-blind comparative study)Bronchial asthmaJPRN-jRCT2080220094Mitsubishi Tanabe Pharma was the original trial sponsor; however Astra Zeneca is now the Responsible Party
已完成
3 期
A Phase II/III Study of TS-152 in Patients with Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to Methotrexate (MTX) TherapyjRCT2080223971Taisho Pharmaceutical co., LTD370
进行中（未招募）
1 期
A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating MutationsAdvanced Solid Tumors Harboring Germline PTEN Inactivating MutationsMedDRA version: 23.0Level: PTClassification code 10071986Term: PTEN gene mutationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004770-22-ATTaiho Oncology, Inc.100
进行中（未招募）
1 期
A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating MutationsAdvanced Solid Tumors Harboring Germline PTEN Inactivating MutationsMedDRA version: 23.0Level: PTClassification code 10071986Term: PTEN gene mutationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004770-22-FRTaiho Oncology, Inc.100